№ lp_1_2_53235
File format: docx Character count: 84823 File size: 230 KB
Year: 2023
Region / City: Australia
Topic: Oncology, Pharmaceutical Submission
Document Type: Pharmaceutical Resubmission
Organization: AstraZeneca Pty Ltd
Author: Not specified
Target Audience: Medical Practitioners
Period of Validity: Ongoing
Approval Date: Not specified
Date of Changes: Not specified
Context: A pharmaceutical resubmission document outlining the use of osimertinib as a first-line treatment for locally advanced or metastatic EGFRm non-small cell lung cancer (NSCLC) in Australia, including previous PBAC considerations and clinical trial data.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
AMIVANTAMAB and Lazertinib PBS Listing Submission for First-Line Treatment of EGFRm NSCLC
Year: 2025
Region / city: Australia
Subject: Oncology, Pharmaceutical Submission
Document Type: Pharmaceutical Benefits Scheme (PBS) Submission
Organ / Institution: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: JANSSEN-CILAG PTY LTD
Target Audience: Medical practitioners, healthcare professionals
Period of validity: Ongoing
Approval Date: Pending
Date of modifications: N/A
AMIVANTAMAB and Lazertinib PBS Listing Submission for First-Line Treatment of EGFRm NSCLC
Year: 2025
Region / city: Australia
Subject: Oncology, Pharmaceutical Submission
Document Type: Pharmaceutical Benefits Scheme (PBS) Submission
Organ / Institution: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: JANSSEN-CILAG PTY LTD
Target Audience: Medical practitioners, healthcare professionals
Period of validity: Ongoing
Approval Date: Pending
Date of modifications: N/A
FIRST-LINE EMPIRICAL ANTIBIOTIC THERAPY FOR SPECIFIC CHILDHOOD INFECTIONS
Version: 3.2
Approval Committee: Children’s Services Review Group, UHS
Date of Approval: 18/10/2017
Ratification Group: Wessex ID / Immunology network
Date of Ratification: 05/07/2017
Signature of ratifying Group Chair: Sanjay Patel
Author’s and job titles: Sanjay Patel, Consultant in Paediatric Infectious Diseases, Saul Faust, Consultant in Paediatric Infectious Diseases, Kieran Hand - Consultant antimicrobial pharmacist, UHS, Caroline Cole – Paediatric Pharmacist, UHS, Andrew Flatt – Consultant microbiologist, Portsmouth, Kordo Saeed – Consultant microbiologist, HHFT, Nick Cortes – Consultant microbiologist, HHFT, Mike Hall – Consultant neonatologist, Southampton
Date issued: 18/10/2017
Review date: 18/10/2020
Key words: Antibiotics, child, stewardship
Main areas affected: Paediatrics, NICU, PICU
Other stakeholders consulted: Written in consultations with specialist teams, UHS
Summary of most recent changes: Amended antibiotic (Ab) recommendations, Clarity on when to start Abs in resp tract infections
Relevant national or international Guidance: No
Consultation document completed: Yes
Total number of pages: 50
Note: Is this document to be published in any other format? Microguide
Technology Advisory Interests Register Topic: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]
Year: TBC
Region / City: TBC
Subject: Medical treatment, Cancer research
Document Type: Advisory Interests Register
Organization / Institution: NICE
Author: Multiple
Target Audience: NICE Committee members, medical experts
Period of Validity: Until 02/12/2025
Approval Date: TBC
Date of Changes: TBC
Osimertinib for Stage IB to IIIA Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation as Adjuvant Therapy
Year: 2021
Region / city: Australia
Topic: Oncology / Pharmaceutical
Document Type: Submission
Agency: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: AstraZeneca Pty Ltd
Target Audience: Medical professionals, regulatory authorities
Validity Period: 2021-2026
Approval Date: 20 April 2021
Modification Date: Not specified
Protocol for the Examination of Resection Specimens from Patients with Primary Non-Small Cell Carcinoma, Small Cell Carcinoma, or Carcinoid Tumor of the Lung
Version: 5.1.0.0
Protocol Posting Date: September 2025
CAP Laboratory Accreditation Program Protocol Required Use Date: June 2026
Note: The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.
Resection: Includes pneumonectomy, lobectomy, segmentectomy, and wedge resection
Carcinoma: Includes non-small cell carcinoma, small cell carcinoma, and carcinoid tumor of the lung
Year: 2025
Region / City: Global
Theme: Medical Protocol, Oncology
Document Type: Protocol
Institution: CAP (College of American Pathologists)
Author: Frank Schneider, MD, Kirtee Raparia, MD, FCAP
Target Audience: Medical professionals in pathology and oncology
Period of Validity: 2025-2026
Approval Date: September 2025
Modification Date: September 2025
Submission for listing of selpercatinib (Retevmo®) for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC)
Year: 2023
Region / city: Australia
Theme: Oncology, Pharmacology
Document type: Pharmaceutical submission
Institution: ELI LILLY AUSTRALIA PTY LTD
Author: Not specified
Target audience: Medical professionals, health policy makers
Effective period: Not specified
Approval date: 3 July 2023
Amendment date: Not specified
Topics: EGFRm First-Line Non-Small